leadf
logo-loader
viewRedx Pharma PLC
(
AIM:REDXFRA:0RX
)

Redx Pharma's CSO Richard Armer outlines development ambitions and clinical targets

Redx Pharma Plc's (LON:REDX) chief scientific officer Richard Armer sat down with Proactive London's Andrew Scott to discuss the opportunities ahead for their cancer and fibrosis portfolios.

Redx is ready to begin first-in-man trials of lead oncology drug, RXC004, in the first half of next year.

Putative fibrosis treatment RXC006 is expected to enter the clinic the year after.

Quick facts: Redx Pharma PLC

Follow
AIM:REDX

Price: 95.75 GBX

Market Cap: £263.1 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Redx Pharma 'building on transactions and financing, focused on moving our...

Redx Pharma PLC's (LON:REDX) Lisa Anson joins Proactive London's Katie Pilbeam to discuss the progress of their pipeline, particularly their clinical pipeline.  Anson recaps on its lead product RXC004 which is in a Phase I clinical trial and is part of a potentially breakthrough group of...

on 11/8/21

2 min read